{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T11:08:32Z","timestamp":1779966512478,"version":"3.53.1"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,19]],"date-time":"2021-12-19T00:00:00Z","timestamp":1639872000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015756","name":"SEIMC","doi-asserted-by":"publisher","award":["COVID-19\/SEIMC-FSG"],"award-info":[{"award-number":["COVID-19\/SEIMC-FSG"]}],"id":[{"id":"10.13039\/501100015756","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Ministerio de Ciencia, Innovaci\u00f3n y Universidades","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.biopha.2021.112572","type":"journal-article","created":{"date-parts":[[2021,12,21]],"date-time":"2021-12-21T22:35:23Z","timestamp":1640126123000},"page":"112572","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Impact of early interferon-\u03b2 treatment on the prognosis of patients with COVID-19 in the first wave: A post hoc analysis from a multicenter cohort"],"prefix":"10.1016","volume":"146","author":[{"given":"Sonsoles","family":"Salto-Alejandre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaira R.","family":"Palacios-Baena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Ram\u00f3n","family":"Arribas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Berenguer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Carratal\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inmaculada","family":"Jarr\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta de","family":"Miguel-Montero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"Rodr\u00edguez-Ba\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jer\u00f3nimo","family":"Pach\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2021.112572_bib1","unstructured":"Johns Hopkins University of Medicine: Coronavirus resource center. [Internet]. 2021. Available from: \u3008https:\/\/coronavirus.jhu.edu\/map.html\u3009."},{"key":"10.1016\/j.biopha.2021.112572_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.552909","article-title":"Comparative review of SARS-CoV-2, SARS-CoV, MERS-CoV, and influenza a respiratory viruses","volume":"11","author":"Abdelrahman","year":"2020","journal-title":"Front Immunol."},{"issue":"13","key":"10.1016\/j.biopha.2021.112572_bib3","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1001\/jama.2020.2648","article-title":"Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72\u00a0314 cases from the chinese center for disease control and prevention","volume":"323","author":"Wu","year":"2020","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.biopha.2021.112572_bib4","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1038\/s41591-020-0968-3","article-title":"Extrapulmonary manifestations of COVID-19","volume":"26","author":"Gupta","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.biopha.2021.112572_bib5","first-page":"1","article-title":"Immune dysregulation and immunopathology induced by SARS-CoV-2 and related coronaviruses - are we our own worst enemy?","author":"Wong","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.biopha.2021.112572_bib6","unstructured":"Zhang Q., Bastard P., Liu Z., Le Pen J., Moncada-Velez M., Chen J., et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science [Internet]. 2020\/09\/24. 2020 Oct 23;370(6515):eabd4570. Available from: \u3008https:\/\/pubmed.ncbi.nlm.nih.gov\/32972995\u3009."},{"key":"10.1016\/j.biopha.2021.112572_bib7","unstructured":"Bastard P., Rosen LB, Zhang Q., Michailidis E., Hoffmann H.-H., Zhang Y., et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science [Internet]. 2020\/09\/24. 2020 Oct 23;370(6515):eabd4585. Available from: \u3008https:\/\/pubmed.ncbi.nlm.nih.gov\/32972996\u3009."},{"key":"10.1016\/j.biopha.2021.112572_bib8","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.coviro.2016.01.001","article-title":"Type I interferons in viral control and immune regulation","volume":"16","author":"Teijaro","year":"2016","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.biopha.2021.112572_bib9","doi-asserted-by":"crossref","unstructured":"Major J., Crotta S., Llorian M., McCabe TM, Gad HH, Priestnall SL, et al. Type I and III interferons disrupt lung epithelial repair during recovery from viral infection. Science [Internet]. 2020\/06\/11. 2020 Aug 7;369(6504):712\u2013717. Available from: \u3008https:\/\/pubmed.ncbi.nlm.nih.gov\/32527928\u3009.","DOI":"10.1126\/science.abc2061"},{"key":"10.1016\/j.biopha.2021.112572_bib10","unstructured":"Hung IF-N., Lung K.-C., Tso EY-K., Liu R., Chung TW-H., Chu M.-Y., et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet (London, England) [Internet]. 2020\/05\/10. 2020 May 30;395(10238):1695\u20131704. Available from: \u3008https:\/\/pubmed.ncbi.nlm.nih.gov\/32401715\u3009."},{"issue":"1","key":"10.1016\/j.biopha.2021.112572_bib11","doi-asserted-by":"crossref","first-page":"8059","DOI":"10.1038\/s41598-021-86859-y","article-title":"Role of interferon therapy in severe COVID-19: the COVIFERON randomized controlled trial","volume":"11","author":"Alavi Darazam","year":"2021","journal-title":"Sci. Rep."},{"issue":"9","key":"10.1016\/j.biopha.2021.112572_bib12","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01061-20","article-title":"A randomized clinical trial of the efficacy and safety of interferon \u03b2-1a in treatment of severe COVID-19","volume":"64","author":"Davoudi-Monfared","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"issue":"6","key":"10.1016\/j.biopha.2021.112572_bib13","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2023184","article-title":"Repurposed ANtiviral Drugs for Covid-19 - interim WHO solidarity trial results","volume":"384","author":"Pan","year":"2021","journal-title":"New. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.biopha.2021.112572_bib14","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/S2213-2600(21)00384-2","article-title":"Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial","volume":"9","author":"Kalil","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.biopha.2021.112572_bib15","unstructured":"Berenguer J., Ryan P., Rodr\u00edguez-Ba\u00f1o J., Jarr\u00edn I., Carratal\u00e0 J., Pach\u00f3n J., et al. Characteristics and predictors of death among 4035 consecutively hospitalized patients with COVID-19 in Spain. Clin Microbiol Infect [Internet]. 2020\/08\/04. 2020 Nov;26(11):1525\u20131536. Available from: \u3008https:\/\/pubmed.ncbi.nlm.nih.gov\/32758659\u3009."},{"key":"10.1016\/j.biopha.2021.112572_bib16","unstructured":"Rodr\u00edguez-Ba\u00f1o J., Pach\u00f3n J., Carratal\u00e0 J., Ryan P., Jarr\u00edn I., Yllescas M., et al. Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19). Clin Microbiol Infect [Internet]. 2020\/08\/27. 2021 Feb;27(2):244\u2013252. Available from: \u3008https:\/\/pubmed.ncbi.nlm.nih.gov\/32860964\u3009."},{"key":"10.1016\/j.biopha.2021.112572_bib17","unstructured":"Guti\u00e9rrez-Guti\u00e9rrez B., Del Toro MD, Borobia AM, Carcas A., Jarr\u00edn I., Yllescas M., et al. Identification and validation of clinical phenotypes with prognostic implications in patients admitted to hospital with COVID-19: a multicentre cohort study. Lancet Infect Dis [Internet]. 2021\/02\/23. 2021 Jun;21(6):783\u2013792. Available from: \u3008https:\/\/pubmed.ncbi.nlm.nih.gov\/33636145\u3009."},{"key":"10.1016\/j.biopha.2021.112572_bib18","doi-asserted-by":"crossref","unstructured":"Berenguer J., Borobia AM, Ryan P., Rodr\u00edguez-Ba\u00f1o J., Bell\u00f3n JM, Jarr\u00edn I., et al. Development and validation of a prediction model for 30-day mortality in hospitalised patients with COVID-19: the COVID-19 SEIMC score. Thorax [Internet]. 2021 Feb 25;thoraxjnl-2020\u2013216001. Available from: \u3008https:\/\/pubmed.ncbi.nlm.nih.gov\/33632764\u3009.","DOI":"10.1136\/thoraxjnl-2020-216001"},{"issue":"2","key":"10.1016\/j.biopha.2021.112572_bib19","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J. Biomed. Inf."},{"issue":"4","key":"10.1016\/j.biopha.2021.112572_bib20","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"61","author":"von Elm","year":"2008","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.biopha.2021.112572_bib21","unstructured":"infection WHOWG on the CC and M of C-19. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis [Internet]. 2020\/06\/12. 2020 Aug;20(8):e192\u2013e197. Available from: \u3008https:\/\/pubmed.ncbi.nlm.nih.gov\/32539990\u3009."},{"issue":"1","key":"10.1016\/j.biopha.2021.112572_bib22","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1186\/s13063-020-04864-4","article-title":"Interferon \u03b2-1a (IFN\u03b2-1a) in COVID-19 patients (INTERCOP): study protocol for a randomized controlled trial","volume":"21","author":"Bosi","year":"2020","journal-title":"Trials"},{"issue":"5","key":"10.1016\/j.biopha.2021.112572_bib23","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1093\/infdis\/jiaa350","article-title":"Interferon-\u03b2-1a inhibition of severe acute respiratory syndrome-coronavirus 2 in vitro when administered after virus infection","volume":"222","author":"Clementi","year":"2020","journal-title":"J. Infect. Dis."},{"issue":"1","key":"10.1016\/j.biopha.2021.112572_bib24","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/s41467-019-13940-6","article-title":"Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV","volume":"11","author":"Sheahan","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2021.112572_bib25","doi-asserted-by":"crossref","unstructured":"Chan JF-W., Yao Y., Yeung M.-L., Deng W., Bao L., Jia L., et al. Treatment With Lopinavir\/Ritonavir or Interferon-\u03b21b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset. J Infect Dis [Internet]. 2015\/07\/21. 2015 Dec 15;212(12):1904\u20131913. Available from: \u3008https:\/\/pubmed.ncbi.nlm.nih.gov\/26198719\u3009.","DOI":"10.1093\/infdis\/jiv392"},{"issue":"17","key":"10.1016\/j.biopha.2021.112572_bib26","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1056\/NEJMoa2015294","article-title":"Interferon beta-1b and lopinavir-ritonavir for middle east respiratory syndrome","volume":"383","author":"Arabi","year":"2020","journal-title":"New Engl. J. Med."},{"issue":"8","key":"10.1016\/j.biopha.2021.112572_bib27","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1001\/jama.2019.22525","article-title":"Effect of intravenous interferon \u03b2-1a on death and days free from mechanical ventilation among patients with moderate to severe acute respiratory distress syndrome: a randomized clinical trial","volume":"323","author":"Ranieri","year":"2020","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.biopha.2021.112572_bib28","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1212\/WNL.56.12.1628","article-title":"Long-term efficacy of interferon-beta-1a in relapsing MS","volume":"56","author":"PRISMS-4","year":"2001","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.biopha.2021.112572_bib29","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S2213-2600(20)30511-7","article-title":"Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"9","author":"Monk","year":"2021","journal-title":"Lancet Respir. Med."},{"issue":"2","key":"10.1016\/j.biopha.2021.112572_bib30","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/j.jinf.2020.09.023","article-title":"A quick prediction tool for unfavourable outcome in COVID-19 inpatients: development and internal validation","volume":"82","author":"Salto-Alejandre","year":"2020","journal-title":"J. Infect."},{"issue":"4","key":"10.1016\/j.biopha.2021.112572_bib31","doi-asserted-by":"crossref","first-page":"e0250796","DOI":"10.1371\/journal.pone.0250796","article-title":"Risk factors for unfavorable outcome and impact of early post-transplant infection in solid organ recipients with COVID-19: a prospective multicenter cohort study","volume":"16","author":"Salto-Alejandre","year":"2021","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.biopha.2021.112572_bib32","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s40263-021-00804-1","article-title":"COVID-19 in patients with multiple sclerosis: associations with disease-modifying therapies","volume":"35","author":"Reder","year":"2021","journal-title":"CNS Drugs"},{"key":"10.1016\/j.biopha.2021.112572_bib33","doi-asserted-by":"crossref","first-page":"668890","DOI":"10.3389\/fmicb.2021.668890","article-title":"Use of protein pegylation to prolong the antiviral effect of IFN against FMDV","volume":"12","author":"Diaz-San Segundo","year":"2021","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.biopha.2021.112572_bib34","doi-asserted-by":"crossref","first-page":"104492","DOI":"10.1016\/j.meegid.2020.104492","article-title":"Extended duration therapy regimens based on PEgylated Interferon for Chronic Hepatitis B patients focusing on hepatitis B surface antigen loss: a systematic review and meta-analysis","volume":"85","author":"Ma","year":"2020","journal-title":"Infect., Genet. Evol."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332221013597?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332221013597?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T11:01:00Z","timestamp":1779966060000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332221013597"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":34,"alternative-id":["S0753332221013597"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2021.112572","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of early interferon-\u03b2 treatment on the prognosis of patients with COVID-19 in the first wave: A post hoc analysis from a multicenter cohort","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2021.112572","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"112572"}}